Please login to the form below
PNH
This page shows the latest PNH news and features for those working in and with pharma, biotech and healthcare.
Alexion and NICE agree confidential discount for Ultomiris use on the NHS
NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... stable after receiving Alexion’s older PNH drug Soliris (eculizumab) for six months or more.
Latest news
-
Novartis receives FDA breakthrough therapy designation for rare disease med
Swiss pharma company Novartis has received a breakthrough therapy designation (BTD) for its experimental medication iptacopan for the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). ... standard of care anti-complement treatment, as well
-
Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial
PNH). The head-to-head PEGASUS study showed that complement C3 inhibitor pegcetacoplan was better than Soliris (eculizumab) at improving haemoglobin levels in adults with PNH, an autoimmune disease characterised by ... PEGASUS involved 80 adults with PNH
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
LNPO23, which is in development for three rare renal diseases as well as haematology for first-line paroxysmal nocturnal hemoglobinuria (PNH), with the first results due in 2020.
-
Alexion eyes Soliris combo with $930m deal to buy Achillion
paroxysmal nocturnal haemoglobinuria (PNH), a rare disease whose treatment is currently dominated by Alexion’s blockbuster complement C5 inhibitor Soliris (eculizumab). ... combination with Soliris in PNH – and follow-up ACH-5228 in phase 1.
-
Amgen takes aim at Alexion’s patents for Soliris
That will force Alexion to defend its IP – specifically covering the drug’s main ingredient, formulation and use to treat PNH – and give Amgen an opportunity to invalidate those claims. ... PNH therapy Ultomiris (ravulizumab), which was granted an
Novartis receives FDA breakthrough therapy designation for rare disease med
Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial
Novartis highlights emerging assets and late-stage pipeline at R&D day
Alexion eyes Soliris combo with $930m deal to buy Achillion
Amgen takes aim at Alexion’s patents for Soliris
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster – also a humanised monoclonal antibody – with more convenient dosing. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with PNH in
-
Drug launches to watch in 2019
Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia gravis, which hit revenues of around $3bn in 2018. ... The follow-up, Ultomiris ALXN1210, is a second
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Drug launches to watch in 2019
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Executive
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
-
Publications Director
-
Competitive Salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Account Management
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Account Manager
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Associate Account Director
-
Competitive Salary
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- bluebird bio aiming to separate business units by year-end
- FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- Clark Health promotes Siân Hurst to managing director role
- ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Merck & Co reveals plans for women’s health spinoff Organon
- Virtual agency The Difference Collective makes new hires to senior team
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- The impact of cancer on mental health during COVID-19
PMHub
KVA Digital
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
